PCRXPacira BioSciences, Inc.
$36.41+54% 1Y
$36.41
$19.1652 weeks$36.41
Latest close: a new 52-week highOct 8, 2026what changed →
The financials
Pacira BioSciences, Inc. by the numbers
Pacira BioSciences, Inc. (PCRX) reported revenue of $192M in Q2 2026 (quarter ended Jun 30, 2026), up 6.2% from the same quarter a year earlier. That came with a gross margin of 77% and net income of $4.7M (2.4% of revenue). For the full year FY2025, revenue was $726M (+3.6% year on year) and net income $7.0M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $192M | $181M | +6.2% |
| Gross profit | $148M | $140M | +5.7% |
| Operating income | $4.3M | $8.5M | −50% |
| Net income | $4.7M | −$4.8M | to a profit |
| Diluted EPS | $0.12 | −$0.11 | to a profit |
Drug Manufacturers, Specialty & Generic
Ranks #19 of 41 by RyuScore